Medtronic Evolut TAVR System Shows Strong Performance at Two Years in Low Risk Trial

 
 

 

 

- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™ transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. Presented virtually today as a late-breaking clinical trial at the EuroPCR 2021 e-Course, results showed the Evolut TAVR platform was non inferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years (4.3% for TAVR versus 6.3% for surgery; p

"We know that TAVR has an advantage over surgery in certain near-term outcomes; however, in these low-risk studies, longer term outcomes are more important than ever. The full two-year data from the randomized Evolut Low Risk Trial demonstrate that between years one and two, patients who have undergone TAVR continue to do exceptionally well with no convergence of the primary outcome curves," said John Forrest , M.D., director of interventional cardiology at the Yale School of Medicine in New Haven, Conn. , and principal investigator in the Evolut Low Risk Trial. "Heart teams can be confident that low-risk patients who undergo TAVR are doing exceptionally well at two years. There are some clear differences in secondary outcomes, and the long-term impact in areas such as hemodynamics, pacemakers, and prosthesis-patient mismatch will be important to follow."

 

At two years, results from the study showed there was no convergence of the divergent Kaplan-Meier curves for death or disabling stroke between TAVR and surgery, demonstrating that improved safety shown early on for TAVR was sustained over time. In addition, results from the study showed:

 
  • Excellent hemodynamic (blood flow) performance for TAVR with statistically significantly lower mean aortic valve gradient (9.0 mm Hg versus 11.7 mm Hg) and larger effective orifice area than surgery (2.2 cm 2 versus 2.0 cm 2 ) at two years, (p
  • Numerically lower rates of death in the TAVR arm (3.5% versus 4.4%), heart failure hospitalizations (5.3% versus 7.1%) and disabling stroke (1.5% versus 2.7%) compared to surgery at two years.
  •  
  • Prosthesis-patient mismatch was lower for TAVR compared to surgery at two years with a difference of 2.1% versus 4.9% in the severe category (p
  • Valve thrombosis rates showed no signs of increase and remained low at two years (0.3% for TAVR versus 0.2% for SAVR).
  •  

The global randomized Evolut Low Risk Trial evaluated three valve generations (CoreValve™, Evolut™ R and Evolut™ PRO valves) across a variety of valve sizes in more than 700 patients with severe aortic stenosis deemed to have a low mortality risk with surgery with a predicted risk of mortality of less than 3%.

 

"Results from this landmark study reassure us that the positive outcomes presented using the Bayesian statistical analysis at ACC.19, before the full two-year outcomes were available, matched the actual two-year outcomes and thus was an extremely accurate and scientifically rigorous methodology that researchers can feel confident about moving forward," said Jeffrey J. Popma , M.D., vice president and chief medical officer for the Coronary & Renal Denervation business and the Structural Heart & Aortic business, which are part of the Cardiovascular Portfolio at Medtronic. "Furthermore, the Evolut TAVR platform continues to show it is a treatment option well-suited for lower-risk patients who are living longer and may be more active."

 

The Evolut TAVR platform, including the Evolut™ R, Evolut™ PRO and Evolut PRO+ TAVR Systems, is indicated for symptomatic patients with severe aortic stenosis across all surgical risk categories (extreme, high, intermediate and low) in the U.S. and countries that recognize CE Mark. It is estimated that 165,000 low-risk patients suffer from severe aortic stenosis per year in the U.S., Western Europe , and Japan . If left untreated, it can cause heart failure in as little as two years.

 

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

 

   About Medtronic
 
Medtronic plc (   www.medtronic.com   ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

 

  Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.    

 
 
          
 

   Contacts:   

 
 
 
 
 

  Joey Lomicky  

 
 

  Ryan Weispfenning  

 
 

  Public Relations  

 
 

  Investor Relations  

 
 

  +1-763-526-2494  

 
 

  +1-763-505-4626  

 
 
 

 

 
 

  Medtronic plc (PRNewsfoto/Medtronic plc) 

 
 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-evolut-tavr-system-shows-strong-performance-at-two-years-in-low-risk-trial-301292874.html  

 

SOURCE Medtronic plc

 

 

 

 Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/May2021/18/c2196.html  

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×